ODM-208
PreclinicalSmall molecule
Orion Corporation, Orion PharmaODM-208 is one of 11 small molecule programs targeting Prostate Cancer Metastatic. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Prostate Cancer Metastatic
#DrugCompanyPhaseTrials
1Zytiga
Johnson & JohnsonPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Opevesostat
Merck & Co.Phase 3
Fludrocortisone Acetate
Merck & Co.Phase 3
Fludara
SanofiPreclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Adi-212
AAdicet Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ODM-208. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details